Skip to main content

NYXH · Nyxoah SA · Webcasts, Transcripts & Audio

Track NYXH — free
$1.36 +0.03 (+2.26%) At close · Oct 2
Market Cap
$147.67M
Shares
101.84M
Volume · Oct 2 68.55K Avg daily vol (3M) 294.76K

Nyxoah SA Webcasts

Earnings calls, investor updates, investor days and conferences for Nyxoah SA (NYXH), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-05
Nyxoah SA (NYXH) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-05
Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript
Confident tone Reimbursement and CMS coding International growth Sales force expansion
Results not yet reported
Audio Transcript Slides 8-K10-Q
Capital Markets Day
Investor event
2026-07-08
Nyxoah SA (NYXH) July 2026 Capital Markets Day Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-12
Nyxoah SA (NYXH) Q1 2026 Earnings Call Transcript
Confident tone Financial Performance / Margins Market Research / Surgeon Adoption Disciplined OpEx / Cash Runway Management
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Nyxoah SA (NYXH) Q4 2025 Earnings Call Transcript
Confident tone U.S. commercial launch momentum Reimbursement and CMS coding Gross margin and next-gen product roadmap
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Nyxoah SA (NYXH) Q3 2025 Earnings Call Transcript
Confident tone U.S. Commercial Launch of Genio Reimbursement and Payer Coverage Gross Margin Trajectory
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-18
Nyxoah SA (NYXH) Q2 2025 Earnings Call Transcript
Confident tone Label differentiation and CCC strategy Reimbursement and VAC/pre-authorization process FDA PMA approval and U.S. launch
Diluted EPS
-0.55
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Nyxoah SA (NYXH) Q1 2025 Earnings Call Transcript
Confident tone CCC (complete concentric collapse) labeling FDA PMA approval and manufacturing validation Reimbursement and CPT code
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Nyxoah SA (NYXH) Q4 2024 Earnings Call Transcript
Confident tone Genio product differentiation and DREAM clinical data Reimbursement and CPT coding Deferred revenue accounting change
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-06-30
Nyxoah SA (NYXH) Q2 2024 Earnings Call Transcript
Confident tone Genio product differentiation European commercial performance GLP-1 drugs and OSA market expansion
Diluted EPS
-0.43
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Nyxoah SA (NYXH) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Nyxoah SA (NYXH) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Nyxoah SA (NYXH) Q2 2023 Earnings Call Transcript
Diluted EPS
-0.45
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Nyxoah SA (NYXH) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Nyxoah SA (NYXH) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Nyxoah SA (NYXH) Q3 2022 Earnings Call Transcript
Diluted EPS
-0.24
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Nyxoah SA (NYXH) Q2 2022 Earnings Call Transcript
Diluted EPS
-0.19
Audio Transcript Slides 8-K10-Q
Showing 1–17 of 17 webcasts
Key facts CIK 1857190 CUSIP B6S7WD106 13F (30d) 2 filings 2 filers Visit website Investor relations